Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.36 |
| ▸ | PER2 | O15055 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891750 | 0.86 | NOTUM (0.50) | HDAC1HDAC8HDAC6NOTUMSRD5A1 | |
| SCHEMBL16480402 | 0.81 | PARP1 (0.46) | NOTUMSRD5A1PER2ALDH1A1 | |
| SCHEMBL9891746 | 0.79 | CNR2 (0.45) | CNR2ALDH1A1HTR7MAPT | |
| SCHEMBL9893128 | 0.77 | PER2 (0.48) | NOTUMSRD5A1PER2ALDH1A1HTR7 | |
| SCHEMBL24717003 | 0.75 | HDAC1 (0.40) | CNR2HDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL9108982 | 0.74 | P2RX7 (0.43) | CNR2CNR1HDAC1HDAC8HDAC6 | |
| SCHEMBL9108987 | 0.74 | P2RX7 (0.43) | CNR2CNR1HDAC1HDAC8HDAC6 | |
| SCHEMBL9891736 | 0.69 | ALDH1A1 (0.41) | HDAC1HDAC8HDAC6NOTUMSRD5A1 | |
| SCHEMBL9891747 | 0.68 | CNR2 (0.47) | CNR2CNR1HDAC1HDAC8HDAC6 | |
| SCHEMBL4748903 | 0.67 | MAPK1 (0.54) | NOTUMALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885HDAC1 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.